Sarah Cannon Research Institute
 | This article contains content that is written like an advertisement. (November 2010) |
 | This article has no links to other Wikipedia articles. (November 2010) |
Sarah Cannon Research Institute (SCRI) is a strategic research organization focusing on advancing therapies for patients and accelerating drug development. With corporate headquarters in Nashville, Tennessee, it conducts community-based clinical trials in oncology, cardiology, gastroenterology and other therapeutic areas through its affiliation with a network of hundreds of physicians. [1]
SCRI has six strategic sites in oncology [2] and 11 in non-oncology [3] around the United States that participate in both industry-sponsored and investigator-initiated trials. SCRI accrued more than 2,500 patients to cancer trials in 2009, including more than 500 to Phase I investigational studies, making it among the largest research institutes in the world. [4] Non-oncology trials accounted for nearly 1,500 additional patients for a total of almost 4,000. [5]
Its Drug Development Program has conducted 70+ “first-in-man” trials. SCRI has been involved in the testing and development of about 10 drugs that have been approved since 1999. [6]
In addition to conducting research through clinical trials, SCRI offers management, regulatory and other support services to drug development sponsors and strategic investigator sites.
SCRI employs over 350 people [6] and was No. 4 on NashvillePost magazine’s 2010 list of the Best Employers in Middle Tennessee. [7]
In 2009 [8]and 2010, SCRI was awarded a spot on Modern Healthcare’s list of the 100 Best Places to Work in Healthcare. [9]
History
SCRI was formed in 2004 through a joint venture between Tennessee Oncology and HCA. Before helping form SCRI, Tennessee Oncology had conducted research on behalf of the Minnie Pearl Research Network since 1993. [10]
In 2006, the company launched SCRI Services, a division that specializes in clinical research services with a focus on oncology drug development programs. [11]
SCRI started a cardiovascular initiative in 2008. [6] Currently, there are three strategic sites for cardiovascular research: Redmond Regional Medical Center in Rome, Georgia, Centennial Heart in Nashville, Tennessee and Osceola Regional Medical Center in Kissimmee, Florida.
The Global Services division was created in 2010 to provide project management, clinical monitoring, data management, biostatistics, safety, medical writing, quality assurance and data safety monitoring boards on a global platform. [12]
Organization
Mission
SCRI is committed to the improvement of patient outcomes and advancement of medical science through innovation and quality execution of clinical research.
Locations
Headquarters
SCRI’s headquarters are in Nashville, Tennessee. Its multi-specialty division is based in Memphis, Tennessee. Sarah Cannon Research UK is headquartered in London, England.
Other locations
SCRI works with 57 sites in 24 states and the United Kingdom. [13] This includes six oncology strategic sites and 11 multi-specialty strategic sites.
Oncology strategic sites include: [2]
- Tennessee Oncology, Nashville, Tennessee
- Florida Cancer Specialists, Fort Myers, Florida
- Oncology Hematology Care, Cincinnati, Ohio
- Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee
- South Carolina Oncology Associates, Columbia, South Carolina
- Virginia Cancer Institute, Richmond, Virginia
Multi-specialty strategic sites include: [3]
- Memphis Gastroenterology Group, Memphis, Tennessee
- Gastrointestinal Associates, Jackson, Mississippi
- The Frist Clinic – Nashville Gastroenterology, Nashville, Tennessee
- Digestive Health Specialists, Tupelo, Mississippi
- Centennial Heart, Nashville, Tennessee
- Redmond Regional Hospital Harbin Clinic, Rome, Georgia
- SCRI Research Center, Germantown, Tennessee
- The Jackson Clinic, Jackson, Tennessee
- Gynecology & Obstetrics, Memphis, Tennessee
- The Women’s Clinic, Ft. Collins, Colorado
- Dermatology East, Germantown, Tennessee
References
- ^ http://sarahcannonresearch.com/about/
- ^ a b http://sarahcannonresearch.com/our-research/oncology/strategic-sites.dot
- ^ a b http://sarahcannonresearch.com/our-research/multispeciality/multispecialty-sites.dot
- ^ http://www.nashvillepost.com/news/2010/3/22/the_added_complexity_is_worth_the_effort
- ^ http://nashville.medicalnewsinc.com/on-trial-considering-clinical-oncology-trials-as-a-first-line-of-offense-cms-2330
- ^ a b c http://www.nashvillepost.com/news/2009/12/28/a_clinical_trial_should_be_your_first_option
- ^ http://www.nashvillepost.com/news/2010/7/9/best_employers_in_middle_tennessee_2010
- ^ http://www.modernhealthcare.com/article/20090908/INFO/909039998
- ^ http://www.modernhealthcare.com/article/20100907/INFO/100909978/-1
- ^ http://nashvillecitypaper.com/content/city-business/%E2%80%98if-we-aren%E2%80%99t-doing-it-we-can%E2%80%99t-expect-anyone-else-to%E2%80%99
- ^ http://sarahcannonresearch.com/about/our-history.dot
- ^ http://www.nashvillepost.com/news/2010/6/3/scri_adds_division_leadership
- ^ http://sarahcannonresearch.com/about-us/map.dot